Amgen drug combined with immunotherapy extends survival in lung cancer trial
A clinical trial shows that Amgen's Imdelltra, when combined with AstraZeneca's Imfinzi, significantly extends survival for patients with extensive-stage small cell lung cancer. The combination reduced the risk of death by 58% compared to immunotherapy alone.
Why it matters
This represents a major advancement in oncology, offering a more effective treatment protocol for an aggressive and difficult-to-treat cancer.
Amgen drug combined with immunotherapy extends survival in lung cancer trial left Amgen said that nearly 80% of trial patients treated with the combination were alive after one year, compared with 53% of those on Imfinzi alone, as patient follow-up continues REUTERS REUTERS https://th-i.thgim.com/public/incoming/hwzhju/article71627313.ece/alternates/FREE_1200/2026-10-23T170013Z_856762213_RC2UZLAGTIZK_RTRMADP_3_CANCER-AMGEN.JPG MIKE BLAKE FILE PHOTO: A view of the Amgen logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in